English

BioStock: CombiGene gears up in epilepsy project

Report this content

Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy. 

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/combigene-gears-up-in-epilepsy-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

 

Subscribe

Documents & Links

Quick facts

BioStock: CombiGene gears up in epilepsy project
Tweet this

Quotes

With the agreement with Viralgen, CombiGene takes a big step towards having a complete production method in place. The few pieces that are missing to start a large-scale production, we expect to get into place within short. We are thus in a position where we will soon have everything in place to start producing materials for the final preclinical studies, including the toxicology and biodistribution studie.
Jan Nilsson, CEO CombiGene